Study details
Enrolling now
Rollover Trial for Povorcitinib
Incyte Corporation
NCT IDNCT06855498ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
600
Study length
about 3 years
Ages
18+
Locations
107 sites in AL, AR, AZ +24
About this study
Researchers are testing a treatment called povorcitinib in people who have already participated in other clinical trials of this drug. The trial will last about 1095 days and involve approximately 600 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take povorcitinib
PhasePhase 3
Drugpovorcitinib
Primary goalProportion of participants with Treatment-Emergent Adverse Events (TEAEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
kinase inhibitor
Endpoints
Primary: Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)